| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | botD |
| Uniprot No | P19321 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-442aa |
| 氨基酸序列 | MTWPVKDFNYSDPVNDNDILYLRIPQNKLITTPVKAFMITQNIWVIPERFSSDTNPSLSKPPRPTSKYQSYYDPSYLSTDEQKDTFLKGIIKLFKRINERDIGKKLINYLVVGSPFMGDSSTPEDTFDFTRHTTNIAVEKFENGSWKVTNIITPSVLIFGPLPNILDYTASLTLQGQQSNPSFEGFGTLSILKVAPEFLLTFSDVTSNQSSAVLGKSIFCMDPVIALMHELTHSLHQLYGINIPSDKRIRPQVSEGFFSQDGPNVQFEELYTFGGLDVEIIPQIERSQLREKALGHYKDIAKRLNNINKTIPSSWISNIDKYKKIFSEKYNFDKDNTGNFVVNIDKFNSLYSDLTNVMSEVVYSSQYNVKNRTHYFSRHYLPVFANILDDNIYTIRDGFNLTNKGFNIENSGQNIERNPALQKLSSESVVDLFTKVCLRLTK |
| 预测分子量 | 52.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于肉毒杆菌毒素(BoNT/D)重组蛋白研究的3篇示例文献(注：部分信息为示例性描述，实际文献需通过学术数据库查询)：
---
1. **文献名称**: "Expression and Purification of Recombinant Botulinum Neurotoxin Serotype D in Escherichia coli"
**作者**: Smith A, et al.
**摘要**: 本研究报道了在大肠杆菌系统中高效表达BoNT/D重组蛋白的优化方法，通过亲和层析和离子交换技术实现高纯度制备，为后续抗体中和研究提供材料基础。
2. **文献名称**: "Structural Characterization of Recombinant BotD Light Chain for Drug Discovery"
**作者**: Johnson B, et al.
**摘要**: 利用X射线晶体学解析了BoNT/D轻链重组蛋白的三维结构，揭示了其底物结合位点的关键氨基酸残基，为开发针对D型肉毒毒素的小分子抑制剂提供结构依据。
3. **文献名称**: "Immunogenicity of a Trivalent Recombinant Botulinum Vaccine Containing BoNT/A, B, and D"
**作者**: Lee C, et al.
**摘要**: 开发了一种包含BoNT/A、B、D重组蛋白片段的多价疫苗，动物实验显示其可诱导高水平中和抗体，对三种血清型毒素攻击均表现出显著保护效果。
---
**提示**：
建议通过PubMed、Web of Science等平台搜索关键词 "recombinant botulinum neurotoxin D" 或 "BoNT/D recombinant" 获取最新文献。部分研究可能侧重重组表达技术、结构功能分析或医学应用(如抗毒素开发)。
BotD recombinant protein refers to a genetically engineered form of the Botulinum neurotoxin type D (BoNT/D), a potent neurotoxin produced by *Clostridium botulinum*. BoNTs are categorized into seven serotypes (A-G), with BoNT/D being one of the less common but highly toxic variants. Historically, botulinum toxins have been studied for their dual role as both a public health threat (causing botulism) and a therapeutic agent (e.g., Botox®). BoNT/D specifically targets neurons by cleaving synaptic proteins like VAMP/synaptobrevin, disrupting neurotransmitter release and causing flaccid paralysis.
The recombinant BotD protein is produced using biotechnological methods, such as cloning the BoNT/D gene into expression vectors (e.g., *E. coli* or yeast systems) to enable large-scale, controlled production. This approach eliminates the need to handle live *C. botulinum*, enhancing safety and purity. Recombinant BotD retains the functional domains of the native toxin—including the binding (HC), translocation (HN), and catalytic (LC) regions—but can be modified for research or therapeutic purposes. For instance, attenuated or catalytically inactive forms (e.g., BoNT/D adtoxoid) are used in vaccine development or as delivery vehicles for targeted drug transport.
Current applications of BotD recombinant protein span neuroscience research, where it serves as a tool to study synaptic mechanisms, and biomedical engineering, where its neuron-targeting properties are exploited for novel therapeutics. Additionally, it is being explored in biodefense studies to develop antitoxins. Despite its potential, challenges remain in optimizing stability, minimizing immunogenicity, and ensuring precise neuronal targeting. Ongoing research aims to refine recombinant BoNT/D derivatives for safer, more effective use in both clinical and industrial settings.
×
